SCHEMBL2690845

SCHEMBL2690845

CCCOC(=O)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
HCAR2 Q8TDS4 1/20 0.35
ALDH1A1 P00352 3/20 0.34
LMNA P02545 1/20 0.33
CES2 O00748 1/20 0.32
ESR1 P03372 1/20 0.32
CHRM1 P11229 1/20 0.32
TSHR P16473 1/20 0.32
SLC6A2 P23975 1/20 0.32
KDR P35968 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
THRB P10828 1/20 0.32
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2693063 0.94 CA1 (0.46) CA1CA2HCAR2ALDH1A1LMNA
SCHEMBL2689521 0.92 CA1 (0.48) CA1CA2HCAR2ALDH1A1LMNA
SCHEMBL2692688 0.92 CA1 (0.48) CA1CA2HCAR2ALDH1A1LMNA
SCHEMBL1314620 0.88 ALDH1A1 (0.47) CA1CA2HCAR2ALDH1A1LMNA
SCHEMBL2691400 0.87 HCAR2 (0.38) CA1CA2HCAR2ALDH1A1LMNA
SCHEMBL2689547 0.86 NAAA (0.46) CA1CA2HCAR2ALDH1A1LMNA
SCHEMBL30528029 0.85 NAAA (0.48) HCAR2ALDH1A1LMNACES2TSHR
SCHEMBL30475146 0.85 NAAA (0.48) HCAR2ALDH1A1LMNACES2TSHR
SCHEMBL2690623 0.85 NAAA (0.48) HCAR2ALDH1A1LMNACES2TSHR
SCHEMBL30475145 0.85 NAAA (0.48) HCAR2ALDH1A1LMNACES2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346622-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-11-13 US claimed
EP-4585601-A1 NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE Daiichi Sankyo Company, Limited (JP) 2025-07-16 EP claimed
EP-4424717-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE Daiichi Sankyo Company, Limited (JP) 2024-09-04 EP claimed
CN-118302451-A Novel oligosaccharide, intermediate for producing the oligosaccharide, and process for producing the same 第一三共株式会社 2024-07-05 CN claimed
WO-2024053574-A1 NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE 第一三共株式会社 2024-03-14 WO claimed
WO-2023074843-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE 第一三共株式会社 2023-05-04 WO claimed
US-20250346622-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-11-13 US disclosed
EP-4585601-A1 NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE Daiichi Sankyo Company, Limited (JP) 2025-07-16 EP disclosed
CN-119080588-A Preparation method of perfluoro isobutyl methyl ether 江苏安靠智电股份有限公司 2024-12-06 CN disclosed
EP-4424717-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE Daiichi Sankyo Company, Limited (JP) 2024-09-04 EP disclosed
CN-118302451-A Novel oligosaccharide, intermediate for producing the oligosaccharide, and process for producing the same 第一三共株式会社 2024-07-05 CN disclosed
WO-2024053574-A1 NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE 第一三共株式会社 2024-03-14 WO disclosed
EP-4318629-A1 PRIMER FOR POWER STORAGE DEVICE ELECTRODES, COMPOSITION FOR FORMING PRIMER LAYER, ELECTRODE FOR POWER STORAGE DEVICES, AND SECONDARY BATTERY AGC INC. (JP) 2024-02-07 EP disclosed
WO-2023074843-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE 第一三共株式会社 2023-05-04 WO disclosed
CN-102471553-B Fluorine-containing copolymer composition and method for producing same ASAHI GLASS CO.,LTD. (JP) 2016-02-10 CN disclosed
EP-2450406-B1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND METHOD FOR PRODUCING SAME ASAHI GLASS CO LTD (JP) 2015-10-14 EP disclosed
CN-102471553-A Fluorine-containing copolymer composition and method for producing same ASAHI GLASS CO LTD 2012-05-23 CN disclosed
EP-2450406-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND METHOD FOR PRODUCING SAME Asahi Glass Company, Limited (JP) 2012-05-09 EP disclosed
US-20120108723-A1 FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS ASAHI GLASS COMPANY, LIMITED (JP) 2012-05-03 US disclosed
US-20070023740-A1 Use of fluorinated esters in fire extinguishing compositions ANSUL, INC. 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346622-A1 NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE FUT6, FUT5, ST3GAL3 CA1 1484/4885CA2 3245/4885HCAR2 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.